Treatment Pathway
Treatment of Sarcoidosis
Sarcoidosis is a multisystem inflammatory disease characterized by noncaseating granulomas, most commonly affecting the lungs and lymph nodes. It often resolves spontaneously but can cause progressive organ damage requiring corticosteroid treatment.
GINA (Global Initiative for Asthma)GOLD (COPD)BTS/SIGN UK GuidelinesATS/ERS (American/European Thoracic Society)WHO
Managing Sarcoidosis effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Sarcoidosis can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Identify and address triggers (allergens, occupational exposures, smoking)
- ✓Inhaled corticosteroid (ICS) is cornerstone of persistent asthma management
- ✓Short-acting bronchodilator (SABA/SAMA) for rescue symptom relief
- ✓Stepwise therapy escalation: ICS → ICS/LABA → add-on biologics if severe
- ✓Pulmonary rehabilitation for COPD (GOLD stage B/C/D)
What to Do Now
- Learn your personal risk factors for Sarcoidosis (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Sarcoidosis
- Use our AI symptom checker to assess whether your symptoms fit an early Sarcoidosis pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Sarcoidosis-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Non-Pharmacological Management
- •Smoking cessation — single most effective intervention in COPD (slows FEV1 decline)
- •Trigger avoidance: dust mites, pet dander, pollen, mould, cold air, NSAIDs
- •Annual influenza vaccination; pneumococcal vaccination in high-risk patients
- •Pulmonary rehabilitation: supervised exercise + education programme
- •Breathing techniques (pursed-lip breathing, diaphragmatic breathing) for COPD
- •Optimise nutritional status; treat obesity as it worsens respiratory mechanics
- •Supplemental oxygen if SpO2 <88% at rest or <92% with significant desaturation on exertion
Treatment Goals
🎯Symptom control: minimal daytime symptoms, no nocturnal waking
🎯Preserved lung function (FEV1 decline minimised in COPD)
🎯Prevention of exacerbations: ≤1 per year
🎯Normal or near-normal physical activity
🎯Avoidance of side effects (steroid complications with high-dose ICS)
Monitoring Parameters
- ◆Spirometry (FEV1, FVC, FEV1/FVC): baseline and annually in COPD; assessment after treatment changes
- ◆Peak expiratory flow (PEF): self-monitoring in asthma (symptom-based or twice daily)
- ◆Oxygen saturation (SpO2): with exacerbations or progressive disease
- ◆Symptom scores: ACQ/ACT (asthma), CAT/mMRC (COPD) at each visit
- ◆Exacerbation frequency: a key driver of treatment escalation in both asthma and COPD
- ◆Inhaler technique review at every clinical encounter
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Sarcoidosis — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Sarcoidosis combined with new relevant symptoms
- ⚠Sudden worsening of Sarcoidosis symptoms despite established treatment
Escalation Criteria
- →Severe acute asthma: PEFR <50% best → hospitalisation, IV corticosteroids, nebulised bronchodilators
- →COPD acute exacerbation: worsening dyspnoea + purulent sputum → antibiotics + systemic corticosteroids
- →Inadequate control on ICS/LABA → consider add-on LAMA, biologics (severe eosinophilic asthma), or specialist referral
- →New respiratory failure (PaO2 <8 kPa, rising CO2) → urgent hospital assessment
Special Populations
Children: weight-appropriate dosing; spacer devices for pMDI; reassess diagnosis at each stage
Pregnancy: ICS and SABA safe; LABA use acceptable if benefit outweighs risk; smoking cessation critical
Elderly: increased risk of ICS-related osteoporosis; co-existing cardiovascular disease may limit beta-agonist use
Athletes: check WADA permitted status for inhaled medications
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →